A single-use bioprocessing training facility in Guangzhou will help attract and retain biopharma talent in the burgeoning China market, says GE Healthcare.
Bioprocess vendor GE Healthcare Life Sciences and Guangzhou Development District government have invested a total of $10 million (‚ā¨9 million) to establish a biomanufacturing training center in the Guangdong province in China.
The Guangzhou Bioprocess Academy aims to train over 1,000 people annually when it opens in September next year and is needed to feed the the rapid growth in biomanufacturing services as China‚Äôs biopharma industry blossoms.
‚ÄúWe know from extensive contact with our customers in the region that attracting and retaining biopharma talent is a huge necessity. Our customers need knowledgeable staff in a short amount of time. With the growth of the biopharma market in China, investing in talent growth is an important way to support the industry,‚ÄĚ Firman Ghouze, chief marketing officer APAC at GE Healthcare Life Sciences told Bioprocess Insider.
‚ÄúIn the near term, we believe that the center will enable many of our customers to train the workforce they need to operate their facilities. In the long run, the center aims to support the growth of the talent pool in Guangdong, and the rest of China. The future growth of the biopharma industry is dependent on highly-skilled professionals.‚ÄĚ
According to some industry reports, China‚Äôs biologics market has grown from under $1 billion in 2012 to a projected $50 billion in 2021.
As such, there have been numerous investments into manufacturing plants, with a focus at least for now on single-use systems to enable speed and flexibility. BeiGene,¬†Lonza, JHL Biotech, Pfizer, and¬†Boehringer Ingelheim have all set up plants based on single-use equipment in the country, for example.
Therefore, Ghouze said, the initial focus at the training center will be on single-use technologies education‚ÄĚ since the China market is developing a great deal of its capacity with this technology. With the development of the biopharma market in China, we anticipate there might be a need to train professionals in stainless-steel technologies as well.‚ÄĚ
It is not just China that lacks bioprocessing expertise ‚Äď the industry as a whole is suffering from gaps in staffing.
GE has been involved with several training centers to help train staff, including partnering with Ireland‚Äôs National Institute for Bioprocessing Research and Training (NIBRT), a government-funded center that trains over 4,000 people a year from its site in Dublin.
GE has also been involved in setting up the Jefferson Institute for Bioprocessing (JIB) near Philadelphia, Pennsylvania, which is somewhat of a franchise of the Ireland institute, being supported by NIBRT‚Äôs curriculum and training program. A similar collaboration is in place at the University of Technology Sydney, Australia where a bioprocessing training-GMP Lite Facility opened its doors in July.
While the Guangzhou Bioprocess Academy is not currently tied-in with NIBRT, ‚ÄúGE, GDD and NIBRT are actively in discussions regarding a training partnership in China and expect to make an announcement in quarter one 2020,‚ÄĚ Ghouze told us.